Our history
Share
Institut Curie's Technology Transfer Office was founded in 2003. It now has over 10 years of experience in the valorization and commercialization of Institut Curie's innovations.
Patents
- 1996: 1st Patent-pending on « Hyperbactericidal surfaces » – Institut Curie Research Center
- 1997: 1st Patent-pending on « Use of Sulphinyl Benzhydryl derivatives for treating drug-induced sleepiness » – Institut Curie Hospital Group
Licencing
- 2002: Commercialization agreement signed with BTG International for medical device
- 2003: Exclusive license with Oncodesign for prostate cancer PDX
- 2005: Exclusive license with Asylum on Atomic Force Microscopy
- 2008: Exclusive license with DNA therapeutics (acquired by ONXEO) for Dbait small molecule
- 2014: Exclusive license with Abbott on Bladder cancer biomarker
Major industrial partnerships
- From 2005: Major industry alliance with Servier, renewed in 2017 (Related news)
- From 2011: Long term partnership with Harmonic Pharma (Related news)
- From 2013: Partnership to develop an antibody for gynecological cancers with GamaMabs Pharma (Related news)
- From 2013: Strengthen translational research in new drug discovery with Roche, renewed in 2017(Related news)
- From 2014: Partnership on epigenetic modification targeting for cancer cure with Inventiva (Related news)
- From 2015: Institut Curie and Sanofi open an industrial Chair IMOCA (Related news)
- From 2016: Collaboration for the development of its immune-oncology program NKR-T with Celyad (Related news)
- From 2016: Framework agreement with BMS (Related news)
Start-ups
- 2002: Dosisoft
- 2006: Xentech
- 2006: DNA therapeutics (acquired by ONXEO)
- 2011: Meiogenix
The history of Institut Curie
Who are we?
Institut Curie has been a recognized public utility foundation since 1921. Since its creation by Marie Curie, it ...
More about us
Share